Historical salary details - Dr. James I. Healy, M.D.,PhD, Director, Rapport Therapeutics Inc.
Dr. James I. Healy, M.D.,PhD is the Director of Rapport Therapeutics Inc.. They also hold 3 other positions in Y-Mabs Therapeutics Inc, Natera Inc and Bolt Biotherapeutics Inc.
Dr. James I. Healy, M.D.,Phd
Director
-
Gross Remuneration
-
Current Company
Rapport Therapeutics Inc.
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | Rapport Therapeutics Inc. | Director | - | - |
| 2024 | Y-Mabs Therapeutics Inc | Chairman of the Board | - | - |
| 2024 | Natera Inc | Independent Director | - | - |
| 2024 | Bolt Biotherapeutics Inc | Lead Independent Director | - | - |
| 2023 | Natera Inc | Independent Director | 329.6 K | -18.8 % |
| 2023 | Y-Mabs Therapeutics Inc | Chairman of the Board | 184.3 K | -18.0 % |
| 2023 | ArriVent BioPharma Inc. | Independent Director | - | - |
| 2023 | Karuna Therapeutics Inc | Independent Director | - | - |
| 2022 | Natera Inc | Independent Director | 406.1 K | 17.5 % |
| 2022 | Coherus Biosciences Inc | Chairman of the Board | 228.7 K | -17.0 % |
| 2022 | Y-Mabs Therapeutics Inc | Chairman of the Board | 224.9 K | -50.3 % |
| 2022 | Bolt Biotherapeutics Inc | Lead Independent Director | 137.2 K | 253.7 % |
| 2022 | NuCana plc - ADR | Chairman of the Board | 17.0 K | -61.9 % |
| 2022 | Ascendis Pharma A/S - ADR | Independent Director | - | - |
| 2022 | Karuna Therapeutics Inc | Independent Director | - | - |
| 2022 | Coherus Biosciences Inc | Independent Director | - | - |
| 2022 | ArriVent BioPharma Inc. | Independent Director | - | - |
| 2021 | Karuna Therapeutics Inc | Independent Director | 611.3 K | -12.0 % |
| 2021 | Y-Mabs Therapeutics Inc | Chairman of the Board | 452.0 K | -5.1 % |
| 2021 | Natera Inc | Independent Director | 345.6 K | 8.2 % |
| 2021 | Coherus Biosciences Inc | Independent Director | 275.6 K | -0.9 % |
| 2021 | Ascendis Pharma A/S - ADR | Independent Director | 60.7 K | 10.9 % |
| 2021 | NuCana plc - ADR | Independent Director | 44.7 K | 18.2 % |
| 2021 | Bolt Biotherapeutics Inc | Lead Independent Director | 38.8 K | - |
| 2020 | Karuna Therapeutics Inc | Independent Director | 695.0 K | 395.2 % |
| 2020 | Y-Mabs Therapeutics Inc | Independent Director | 476.2 K | 101.4 % |
| 2020 | Natera Inc | Independent Director | 319.4 K | -33.7 % |
| 2020 | Coherus Biosciences Inc | Independent Director | 278.2 K | 28.5 % |
| 2020 | Ascendis Pharma A/S - ADR | Independent Director | 54.8 K | -5.7 % |
| 2020 | NuCana plc - ADR | Independent Director | 37.8 K | 16.8 % |
| 2020 | Iterum Therapeutics Plc | Independent Director | - | - |
| 2020 | Bolt Biotherapeutics Inc | Independent Director | - | - |
| 2019 | Natera Inc | Independent Director | 481.8 K | 136.9 % |
| 2019 | Y-Mabs Therapeutics Inc | Independent Director | 236.4 K | 6.8 % |
| 2019 | Coherus Biosciences Inc | Independent Director | 216.4 K | 8.3 % |
| 2019 | Karuna Therapeutics Inc | Independent Director | 140.4 K | - |
| 2019 | Iterum Therapeutics Plc | Independent Director | 121 K | 15.4 % |
| 2019 | Ascendis Pharma A/S - ADR | Independent Director | 58.1 K | - |
| 2019 | NuCana plc - ADR | Independent Director | 32.3 K | 7.6 % |
| 2018 | Y-Mabs Therapeutics Inc | Independent Director | 221.4 K | - |
| 2018 | Natera Inc | Independent Director | 203.4 K | 55.5 % |
| 2018 | Coherus Biosciences Inc | Independent Director | 199.8 K | -48.3 % |
| 2018 | Iterum Therapeutics Plc | Independent Director | 104.9 K | - |
| 2018 | NuCana plc - ADR | Independent Director | 30.0 K | 289.7 % |
| 2018 | PDS Biotechnology Corporation | - | 21.5 K | -85.6 % |
| 2018 | PDS Biotechnology Corporation | Independent Director | - | - |
| 2018 | Karuna Therapeutics Inc | Independent Director | - | - |
| 2018 | Ascendis Pharma A/S - ADR | Independent Director | - | - |
| 2017 | Coherus Biosciences Inc | Independent Director | 386.3 K | 108.7 % |
| 2017 | PDS Biotechnology Corporation | Independent Director | 149.6 K | 13.0 % |
| 2017 | Natera Inc | Independent Director | 130.8 K | -13.6 % |
| 2017 | Altamira Therapeutics Ltd | Vice Chairman of the Board | 11.3 K | - |
| 2017 | NuCana plc - ADR | Independent Director | 7.7 K | - |
| 2017 | Y-Mabs Therapeutics Inc | Independent Director | - | - |
| 2017 | Iterum Therapeutics Plc | Director | - | - |
| 2017 | Ascendis Pharma A/S - ADR | Independent Director | - | - |
| 2016 | Coherus Biosciences Inc | Independent Director | 185.1 K | -78.7 % |
| 2016 | Amarin Corp - ADR | - | 157.7 K | -46.3 % |
| 2016 | Natera Inc | Independent Director | 151.4 K | 493.8 % |
| 2016 | PDS Biotechnology Corporation | Independent Director | 132.4 K | -35.1 % |
| 2016 | Altamira Therapeutics Ltd | Vice Chairman of the Board | - | - |
| 2016 | Ascendis Pharma A/S - ADR | Independent Director | - | - |
| 2016 | Amarin Corp - ADR | Independent Director | - | - |
| 2016 | NuCana plc - ADR | Independent Director | - | - |
| 2015 | Coherus Biosciences Inc | Independent Director | 870.6 K | 458.6 % |
| 2015 | Amarin Corp - ADR | Independent Director | 293.7 K | 87.8 % |
| 2015 | PDS Biotechnology Corporation | Independent Director | 204.0 K | - |
| 2015 | Natera Inc | Independent Director | 25.5 K | - |
| 2015 | Ascendis Pharma A/S - ADR | Independent Director | - | - |
| 2015 | Altamira Therapeutics Ltd | Vice Chairman of the Board | - | - |
| 2014 | Amarin Corp - ADR | Independent Director | 156.4 K | 37.6 % |
| 2014 | Coherus Biosciences Inc | Independent Director | 155.9 K | - |
| 2014 | Ascendis Pharma A/S - ADR | Independent Director | - | - |
| 2014 | PDS Biotechnology Corporation | Independent Director | - | - |
| 2014 | Natera Inc | Independent Director | - | - |
| 2014 | Altamira Therapeutics Ltd | Independent Director | - | - |
| 2013 | Amarin Corp - ADR | Independent Director | 113.7 K | -72.0 % |
| 2013 | Altamira Therapeutics Ltd | Independent Director | - | - |
| 2013 | Coherus Biosciences Inc | Independent Director | - | - |
| 2013 | Ascendis Pharma A/S - ADR | Independent Director | - | - |
| 2012 | Amarin Corp - ADR | Independent Director | 405.8 K | 1059.4 % |
| 2011 | Amarin Corp - ADR | Independent Director | 35 K | -74.9 % |
| 2010 | Amarin Corp - ADR | Independent Non-Executive Director | 139.4 K | 257.4 % |
| 2009 | Amarin Corp - ADR | Non-Executive Director | 39 K | 34.5 % |
| 2008 | Amarin Corp - ADR | Non-Executive Director | 29 K | - |